Due to the pharmaceutical industry's cold spell, an increasing number of enterprises are facing insufficient cash flow to support a multitude of clinical trials. Consequently, there is a rising trend of termination of clinical trials. It is well-known that the collaboration between CTTQ and Wuxi Apptec is very close.
Here we summarize the clinical trials terminated or suspended by Chia Tai-Tianqing:
1. TQB3015 for cancer: ATR inhibitor
CTR20233919: phase 1 trial suspended without explanation
Initiated in 2023.12.05, suspended in 2023.12.19
2. TQC3564 for asthma: CRTH2 antagonist
CTR20220230: phase 1b study terminated as strategy adjustment
Initiated in 2022.1.29, terminated in 2023.5.9
3. TQC3564 for allergic rhinitis: CRTH2 antagonist
CTR20220964: phase 1b study terminated as strategy adjustment
Initiated in 2022.8.17, terminated in 2023.5.9
4. TQB3823 for cancer: PARP inhibitor
CTR20211789: phase 1 trial terminated as strategy adjustment
Initiated in 2021.9.14, terminated in 2023.7.1
5. TQ-B3525 for CLL/SLL: PI3Kα/δ inhibitor
CTR20202705: phase 1b/2 trial terminated as strategy adjustment
Initiated in 2021.5.24, terminated in 2023.11.22
6. TQ-B3525 for MCL: PI3Kα/δ inhibitor
CTR20200773: phase 2 trial terminated as strategy adjustment
Initiated in 2020.7.1, suspended in 2023.10.10
7. TQ-B3139 for NSCLC: ALK/ROS1 inhibitor
CTR20220230: phase 2 study terminated as slow patient enrollment (34 pts enrolled since 2020)
Initiated in 2020.8.4, terminated in 2022.3.28
8. TQ-B3139 for NSCLC: ALK/ROS1 inhibitor
CTR20200428: phase 2 study terminated as slow patient enrollment
Initiated in 2019.8.21, terminated in 2023.10.24
9. TQB3602 for MM: proteasome inhibitor
CTR20200258: phase 1 trial terminated as a commercial decision
Initiated in 2020.5.13, terminated in 2023.7.17
10. TQB34559 for blood cancer: IDH2 inhibitor
CTR20192368: phase 1 study terminated as slow patient enrollment (1 pt enrolled since 2020)
Initiated in 2020.3.25, terminated in 2021.3.15
11. Unecritinib (TQ-B3101) for NSCLC: ALK/ROS1/MET inhibitor
CTR20223411: phase 3 trial terminated as strategy adjustment
Initiated in 2023.1.10, terminated in 2023.6.26
12. Unecritinib (TQ-B3101) for cancer: ALK/ROS1/MET inhibitor
CTR20210926: phase 2 trial terminated as a slow progression
Initiated in 2021.9.28, terminated in 2023.10.26
13. TQB2858 for cancer: anti-PD-L1/TGF-β antibody
CTR20212102: phase 1 trial terminated as a slow progression
Initiated in 2021.11.2, terminated in 2022.9.7
14. TQB2858 for pancreatic cancer: anti-PD-L1/TGF-β antibody
CTR20213454: phase 1 trial terminated as pipeline adjustment
Initiated in 2022.2.23, terminated in 2023.8.23
15. TQB2858 for soft tissue sarcoma: anti-PD-L1/TGF-β antibody
CTR20213001: phase 1 trial terminated as reference BsAbs clinical results consideration
Initiated in 2021.11.22, terminated in 2023.2.7
16. TQB2858 for cervical cancer: anti-PD-L1/TGF-β antibody
CTR20212698: phase 1 trial terminated as reference BsAbs clinical results consideration
Initiated in 2022.1.13, terminated in 2022.9.9
17. TQB3820 for blood cancer: Aiolos/Ikaros degrader
CTR20211930: phase 1 study terminated as not meeting the expectation
Initiated in 2021.8.25, terminated in 2023.10.18
18. TQH3910 for PsA: Undisclosed
CTR20221197: phase 1 study terminated as strategy adjustment
Initiated in 2022.6.9, terminated in 2022.11.18
19. TQ05105 for myelofibrosis: JAK1/2 and ROCK1/2 inhibitor
CTR20220784: phase 1b trial terminated as a slow progression
Initiated in 2022.7.14, terminated in 2023.10.8
20. TQ05105 for aGVHD: JAK1/2 and ROCK1/2 inhibitor
CTR20211289: phase 1 trial terminated as a slow progression
Initiated in 2022.6.10, terminated in 2023.6.15
21. TQB2450 for cholangiocarcinoma: anti-PD-L1 antibody
CTR20212456: phase 3 study terminated as competition and commercial reason
Initiated in 2021.1.26, terminated in 2023.2.1
22. TQB2450 for HNSCC: anti-PD-L1 antibody
CTR20190292: phase 3 study terminated as strategy adjustment
Initiated in 20219.7.8, terminated in 2023.8.10
23. TQB3824 for cancer: CDC7 inhibitor
CTR20211918: phase 1 study terminated as strategy adjustment
Initiated in 2021.8.19, terminated in 2023.8.16
24. TQ05105 for myelofibrosis: JAK1/2 and ROCK1/2 inhibitor
CTR20211289: phase 1b trial terminated as a slow progression
Initiated in 2022.7.14, terminated in 2023.10.8
25. TQ05510 for type 2 diabetes: DPP4 inhibitor
CTR20201230: phase 1b study terminated as efficacy consideration
Initiated in 2020.8.5, terminated in 2021.1.20
26. TQB3303 for solid tumors: CDK4/6 inhibitor
CTR20211289: phase 1b trial terminated as a strategy adjustment
Initiated in 2020.9.14, terminated in 2023.8.20
27. Anlotinib for gastric and adenocarcinoma of esophagogastric junction cancer: VEGFR-1/2/3 inhibitor
CTR20200753: phase 3 study terminated as a slow progression
Initiated in 2020.8.10, terminated in 2023.12.10
28. TQB3473 for blood cancer: SYK inhibitor
CTR20200666: phase 1 trial terminated as a strategy adjustment
Initiated in 2020.9.10, terminated in 2023.6.30
29. TQB3562 for solid tumors: IDO inhibitor
CTR20200427: phase 1 trial terminated as a strategy adjustment
Initiated in 2020.6.2, terminated in 2023.7.19
30. AL2846 for NSCLC with bone mets: c-MET inhibitor
CTR20200413: phase 2 trial terminated as difficult to obtain clinical endpoints
Initiated in 2020.9.8, terminated in 2020.11.13
31. TQB3456 for NSCLC: EGFR inhibitor
CTR20181470: phase 1 trial terminated as strategy adjustment
Initiated in 2018.7.20, terminated in 2020.10.10
32. TQB2868 for cervical cancer: anti-PD-1/TGF-β antibody
NCT05998941: phase 2 trial withdrawal as a slow progression (phase 1 study ongoing)
Initiated in 203.8.21, terminated in 2023.11.20
Comments